Real world evidence of the usage of tofacitinib in Ulcerative Colitis patients in Lebanon

Study identification

• EU PAS number:
  EUPAS38515
• Study ID:
  48631
• Official title and acronym:
  Real world evidence of the usage of tofacitinib in Ulcerative Colitis patients in Lebanon
• DARWIN EU® study:
  No
• Study countries:
  Lebanon
• Study description:
  A retrospective cohort study that describes the effectiveness of tofacitinib for the treatment of patients with ulcerative colitis in Lebanon.
• Study status:
  Finalised

Research institutions and networks

Institutions

Pfizer

American University of Beirut

Study timelines

Date when funding contract was signed

Planned:08/11/2021

Actual:08/11/2021

Study start date

Planned:30/11/2021

Actual:30/11/2021

Date of final study report

Planned:30/03/2023

Actual:23/01/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable